ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Perspective Therapeutics Inc

Perspective Therapeutics Inc (CATX)

12,315
-0,025
(-0,20%)
Geschlossen 07 November 10:00PM
12,34
0,025
(0,20%)
Nach Börsenschluss: 10:10PM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
12,315
Gebot
-
Fragen
-
Volumen
697.026
12,18 Tagesbereich 12,74
2,201 52-Wochen-Bereich 19,05
Marktkapitalisierung
Handelsende
12,34
Handelsbeginn
12,51
Letzte Trade
67734
@
12.34
Letzter Handelszeitpunkt
Finanzvolumen
US$ 8.681.529
VWAP
12,4551
Durchschnittliches Volumen (3 Mio.)
834.166
Ausgegebene Aktien
67.430.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-17,85
Gewinn pro Aktie (EPS)
-0,69
Erlöse
1,43M
Nettogewinn
-46,51M

Über Perspective Therapeutics Inc

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers incl... Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company¿s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. Mehr anzeigen

Sektor
Eating Places
Branche
Surgical,med Instr,apparatus
Hauptsitz
Wilmington, Delaware, USA
Gegründet
1983
Perspective Therapeutics Inc is listed in the Eating Places sector of the Amerikanische Börse with ticker CATX. The last closing price for Perspective Therapeutics was US$12,34. Over the last year, Perspective Therapeutics shares have traded in a share price range of US$ 2,201 to US$ 19,05.

Perspective Therapeutics currently has 67.430.000 shares in issue. The market capitalisation of Perspective Therapeutics is US$832,09 million. Perspective Therapeutics has a price to earnings ratio (PE ratio) of -17.85.

CATX Neueste Nachrichten

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

[212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi)Prolonged progression-free survival and tumor response were observed in...

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.5054.2760372565611.8112.911.445129512.01681858CS
4-0.785-5.9923664122113.113.3459.6680300912.40228259CS
12-0.325-2.5712025316512.6416.559.6683416613.48245222CS
26-6.085-33.070652173918.419.058.16213478014.12046107CS
529.686368.4290604792.62919.052.201245822012.5729788CS
1568.552227.265479673.76319.052.05170970211.25704823CS
2608.552227.265479673.76319.052.05170970211.25704823CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
FOXOFOXO Technologies Inc
US$ 0,79
(480,46%)
935,44M
TMQTrilogy Metals Inc
US$ 1,035
(81,90%)
83,28M
DPSTDirexion Daily Regional Banks Bull 3X Shares
US$ 154,45
(40,00%)
3,98M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 83,24
(26,12%)
7,57M
ETHU2x Ether ETF
US$ 5,85
(22,90%)
9,26M
MSOXAdvisorShares MSOS Daily Leveraged ETF
US$ 0,935
(-54,83%)
30,26M
WEEDRoundhill Cannabis ETF
US$ 21,1175
(-29,25%)
28,73k
FIATYieldmax Short Coin Option Income Strategy ETF
US$ 11,59
(-28,68%)
1,49M
MSOSAdvisorshares Pure Us Cannabis Etf
US$ 4,986
(-27,42%)
49,34M
MJUSAmplify US Alternative Harvest ETF
US$ 1,0701
(-26,71%)
199,42k
FOXOFOXO Technologies Inc
US$ 0,79
(480,46%)
913,06M
XLFFinancial Select Sector
US$ 49,55
(6,08%)
143,7M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 34,12
(8,73%)
93,91M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 6,135
(-7,47%)
83,83M
TMQTrilogy Metals Inc
US$ 1,035
(81,90%)
82,82M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock